文献速递妇科肿瘤

尼拉帕利个体化起始剂量在PRIMA/ENGOT-OV26/GOG-3012一线维持治疗试验中的耐受性

Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy.
PubMed 文献 · Eur J Cancer · 2024-06-10

该事后分析基于PRIMA/ENGOT-OV26/GOG-3012试验中接受个体化起始剂量(ISD)的255例新诊断晚期卵巢癌患者,评估常见血液学与非血液学治疗中出现的不良事件(TEAE)的发生时间、持续时间及缓解情况。尼拉帕利组首次血液学TEAE中位发生时间为22.0–35.0天,非血液学TEAE为7.0–56.0天;首次血液学TEAE缓解率≥89.8%,中位持续时间≤16.0天。结论认为ISD总体耐受性良好,TEAE可管理。

要点

  • 尼拉帕利ISD组首次血液学TEAE中位发生时间22.0–35.0天,非血液学TEAE为7.0–56.0天。
  • 首次血液学TEAE缓解率≥89.8%,中位持续时间≤16.0天。
  • 非血液学TEAE缓解率55.3%(失眠)至86.0%(恶心),中位持续时间18.0天(恶心)至134.0天(失眠)。

核心结论

  • 尼拉帕利个体化起始剂量总体耐受性良好,TEAE可管理。
  • 常见血液学和非血液学TEAE发生较早,首次血液学TEAE持续时间短(约2周)且缓解率高。
  • 这些发现支持在尼拉帕利开始后立即密切监测,并可能有助于告知患者对尼拉帕利安全性的预期。

研究设计与样本

  • PRIMA/ENGOT-OV26/GOG-3012(NCT02655016)为3期试验,方案修订后新入组患者根据基线体重/血小板计数接受个体化起始剂量(ISD)。
  • 本事后分析在ISD安全性人群中按治疗组评估常见任何级别血液学(血小板减少、贫血、中性粒细胞减少)和非血液学(恶心、乏力/疲劳、便秘、失眠、高血压)TEAE首次发生的时间、持续时间和缓解情况(数据截止2021年11月17日;中位随访3.5年)。
  • 733例随机患者中,255例在ISD方案修订后入组并接受至少1剂研究治疗(尼拉帕利169例;安慰剂86例)。

主要发现

  • 尼拉帕利组首次血液学TEAE的中位发生时间为22.0–35.0天,非血液学TEAE为7.0–56.0天。
  • 首次血液学TEAE在≥89.8%的患者中缓解;非血液学TEAE缓解率范围为55.3%(失眠)至86.0%(恶心)。
  • 首次血液学TEAE的中位持续时间≤16.0天,首次非血液学TEAE的中位持续时间为18.0天(恶心)至134.0天(失眠)。

临床怎么用

  • 原文结论指出这些发现支持在尼拉帕利开始后立即密切监测,并可能有助于告知患者对尼拉帕利安全性的预期。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To explore safety and tolerability parameters for the niraparib individualized starting dose (ISD) in patients with newly diagnosed advanced ovarian cancer that responded to platinum-based chemotherapy who participated in the phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial (NCT02655016). METHODS: The PRIMA protocol was amended so newly enrolled patients received an ISD based on baseline body weight/platelet count. In this ad hoc analysis, the timing, duration, and resolution of the first occurrence of common any-grade hematologic (thrombocytopenia, anemia, neutropenia) and nonhematologic (nausea, asthenia/fatigue, constipation, insomnia, hypertension) treatment-emergent adverse events (TEAEs) were evaluated by treatment arm in the ISD safety population (data cutoff, November 17, 2021; median follow-up, 3.5 years). RESULTS: Of 733 randomized patients, 255 were enrolled after the ISD protocol amendment and received ≥ 1 dose of study treatment (niraparib, 169; placebo, 86). In the niraparib arm, median times to first events were 22.0-35.0 days for hematologic TEAEs and 7.0-56.0 days for nonhematologic TEAEs. First events resolved in ≥ 89.8% of patients for hematologic TEAEs; for nonhematologic TEAEs, resolution rates ranged from 55.3% (insomnia) to 86.0% (nausea). Median durations of first hematologic TEAEs were ≤ 16.0 days, but for first nonhematologic TEAEs ranged from 18.0 days (nausea) to 134.0 days (insomnia). CONCLUSION: The niraparib ISD was generally well tolerated and TEAEs were manageable. Common hematologic and nonhematologic TEAEs occurred early and first events of hematologic TEAEs had a short duration (≈ 2 weeks) and a high resolution rate. These findings support close monitoring immediately following niraparib initiation and may help inform patient expectations for niraparib safety.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Vulsteke C, Chambers SK, Pérez MJR, et al. Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy. Eur J Cancer. 2024. PMID: 39013265. doi:10.1016/j.ejca.2024.114157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。